HER2-positive breast cancer may be a misnomer, according to a growing body of evidence that one of the most widely ... By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

the body often makes too much of the HER2neu protein, and cells can grow out of control. HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to ...

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall ...

Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Metastatic, or advanced, cancer means that the disease has spread to distant parts of the body and cannot be ... that ...

Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab ... line therapy of HER2-positive breast cancer that has already spread in the body.

The antibody-drug conjugate trastuzumab deruxtecan has been approved since January 2021 for pretreated adults with HER2-positive breast cancer that has metastasized or can no longer be operated on.